期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 148, 期 -, 页码 252-289出版社
ELSEVIER
DOI: 10.1016/j.addr.2018.10.011
关键词
Alzheimer's disease (AD); Parkinson's disease (PD); Blood brain barrier (BBB); Brain-targeted nanoparticles; Nanomedicine; Neurodegenerative disorders; Neuroimaging; Single photon emission computed tomography (SPECT/CT); Magnetic resonance imaging (MRI); Theranostics; Neurotheranostics
资金
- University of Nebraska Foundation
- National Institutes of Health USA [P01 MH64570, RO1 MH104147, P01 DA028555, RO1 NS36126, P01 NS31492, 2R01 NS034239, P01 NS43985, P30 MH062261, RO1 AG043540]
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide optimal therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases. (C) 2018 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据